CENTOGENE takes ownership in Pearl Medical Analysis Lab in Abu Dhabi
We are pleased to announce a significant milestone in CENTOGENE’s continued commitment to advancing precision medicine in the Middle East: […]
We are pleased to announce a significant milestone in CENTOGENE’s continued commitment to advancing precision medicine in the Middle East: […]
We had a wonderful time celebrating the official opening of the CENTOGENE APAC office in Taiwan!Colleagues and friends from across […]
We are excited to announce that CENTOGENE will be participating in the ESHG – European Society of Human Genetics Conference […]
Introducing a new option: CentoScreen Exome Designed for low-risk couples with no known family history of genetic disorders, CentoScreen Exome […]
CENTOGENE is now offering a new NGS Panel area focus on Pediatric disorders. Combining pediatric-focused curation, advanced genomic technologies, and deep scientific expertise.
We´re thrilled to be part of the European Society of Cardiology Congress! Join us in Madrid from August 29 to […]
The future of reproductive medicine meets innovation in Paris. CENTOGENE is proud to be part of 𝘁𝗵𝗲 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 𝗼𝗳 […]
On the occasion of ESHG2025 – the European Congress dedicated to human genetics taking place in Milan – we are […]
The future of human genetics meets innovation in Milan. CENTOGENE is proud to be part of ESHG European Society of […]
We are proud to announce a strategic acquisition of a diagnostic company in Brazil. This achievement represents the fusion of CENTOGENE’s decades-long excellence in diagnostics and quality with years of pioneering experience in reproductive genetics — led by Marcia Riboldi
The future of reproductive genetics guided through Precision Medicine begins now!
We are especially proud to announce the launch of PGT-A test (Preimplementation Genetic Test for Aneuploidy) performed on biopsies of embryos created through FIV.
When Every Second Counts, Genetic Insights Can Save Lives. Now available, one of the world’s most comprehensive Whole Genome Sequencing (WGS) tools for diagnosing genetic diseases—now with results in just 5 business days!
For patients in ICU, neonatal, and emergency settings, a rapid genetic diagnosis is crucial!
Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has concluded its strategic review process and has entered into a Share Purchase Agreement (“SPA”) pursuant to which its operating subsidiaries will be sold to an affiliate of Charme Capital Partners Limited (“Charme”), a pan-European private equity firm, for a cash purchase price of EUR 8,717,906.80.
CENTOGENE received a notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE’S common stock from Nasdaq.
Initial data from largest international Parkinson’s disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these individuals potential candidates to be included in gene-targeted trials
